EICHOR
● Active Not Recruiting
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
Condition: Hypertension · Sponsor: Mineralys Therapeutics Inc.
About this study
This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypertension
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (177)
| Accel Research Sites (ARS) - Birmingham Clinical Research Unit | Birmingham, Alabama, United States | — |
| G & L Research LLC | Foley, Alabama, United States | — |
| Chandler Clinical Trials | Chandler, Arizona, United States | — |
| Arizona Kidney | Glendale, Arizona, United States | — |
| AKDHC Medical Research Services, AZ | Phoenix, Arizona, United States | — |
| Noble Clinical Research | Tucson, Arizona, United States | — |
| Del Sol Research Management, LLC | Tucson, Arizona, United States | — |
| Entertainment Medical Group, Inc | Beverly Hills, California, United States | — |
| CA Institute of Renal Research, CA | Chula Vista, California, United States | — |
| Amicis Research Center - Vacaville | Fairfield, California, United States | — |
| Amicis Research Center - Granada Hills | Granada Hills, California, United States | — |
| Marvel Clinical Research 002, LLC | Huntington Beach, California, United States | — |
+ 165 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.